Navigation Links
Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer

being studied as a single agent and in combination with docetaxel chemotherapy in two Phase 3 clinical trials expected to enroll approximately 1,200 patients with metastatic HRPC. Cell Genesys received Special Protocol Assessments (SPA) from the Food and Drug Administration (FDA) for each of the Phase 3 studies and has also received Fast Track designation for the product. GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently developing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties tha
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
11. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... Mass. , July 10, 2014  Decision ... of surveyed infectious disease (ID) specialists are willing ... Company,s Orbactiv (oritavancin) for use as OPAT, approximately ... prescribe these agents to their hospital inpatients. However, ... of OPAT patients are initiated on OPAT following ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... , CULVER CITY, Calif., Sept. 21 ... services in Southern California, announced the appointment of William Frea, Ph.D., BCBA-D, ... of the Los Angeles Chapter of Autism Speaks . ... a part of an organization that is so committed to the autism ...
... , Physicians and patient to share insights on ... Representatives from the Kennedy Krieger Institute will take part in the ... in Baltimore, Md., joining more than 1,200 of the world,s most influential ... , , Concurrent Session , SOCIETY TRACK: ...
Cached Medicine Technology:Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks 2Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks 3Kennedy Krieger Institute to Participate in 2009 World Stem Cell Summit 2Kennedy Krieger Institute to Participate in 2009 World Stem Cell Summit 3
(Date:7/12/2014)... 12, 2014 The Chicken Egg ... past five years, buoyed by stable demand for industry ... system. “Eggs are a relatively affordable staple for most ... consumption generally grows in line with the size of ... Furthermore, demand for new specialty egg products with enriched ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... to guarantee that a surgical technique used to grind up ... the risk of spreading cancer to other parts of a ... panel to the Food and Drug Administration also said that ... morcellation -- should sign a written consent stating that they ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE (Long Term Evolution). ... continues to grow due to the rapid evolution of ... data traffic, which is a major driver for the ... Measurement equipment comply with industry standards, and services which ... Market is estimated to grown from $3.75 billion in ...
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... 12, 2014 With prom shopping reaching ... and retailer, is ready to showcase its new and ... collection of evening dresses in its online shop. Additionally, ... off) for these elegant gowns. According to the company’s ... on July 26, 2014. , He says, “Now, ...
Breaking Medicine News(10 mins):Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... and the University of Florida Proton Therapy Institute have formed ... The announcement follows the approval of the first clinical study ... cancers in children younger than 3 years old. ... to receive proton therapy at the UF Proton Therapy Institute ...
... respiratory disease, often leading to disability or an increased ... Studies led by Deborah Young-Corbett, a faculty member ... specific types of sanding tools are highly effective in ... the industry,s usage of the available technology remains very ...
... -- The lives of almost 4 million women, newborns, ... year if well-established, affordable health care interventions reached 90 ... the national science academies of seven African countries. ... save lives, says the report, which calls on scientists, ...
... ... Texas , is sponsoring a new video contest inviting participants to describe why they are ... worth up to $15,000, and submitted videos will be shown on Austin Dental Spa’s website ... ...
... ... Self-service Kiosks and Pricing Transparency Patient Estimations. , ... Denver, CO (PRWEB) November 9, 2009 ... a partnership that provides patients more control when interacting with providers by understanding ...
... ... Ask4UFE to launch a podcast series that helps women suffering in silence understand their ... ... but they are life altering, says supermodel Beverly Johnson, during a new 3-part ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 2Health News:Austin Cosmetic Dentist Offers $15,000 Worth of Dental Work in Most Interesting Patient in the World Video Contest 3Health News:FHS Corp. Announces Partnership with Vecna Technologies 2Health News:New Series of Podcasts Highlight Supermodel's "Life-altering" Experience to Raise Awareness of Fibroid Treatment Options 2
Disposable Feather Blades, 50 per pack...
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Standard knife with box, C profile...
Medicine Products: